NL-OMON27076
招募中
不适用
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone
VU University Medical Center0 个研究点目标入组 195 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- constipationmethylnaltrexoneopioidobstipatie
- 发起方
- VU University Medical Center
- 入组人数
- 195
- 状态
- 招募中
- 最后更新
- 2年前
概览
简要总结
/A
研究者
入排标准
入选标准
- •. Age \>/\= 18 years 2\. Receiving palliative care 3\. Life expectancy \> 2 weeks 4\. Able to give informed consent 5\. Receiving opioid treatment with either morphine sulphate, oxycodone or fentanyl 6\. Opioid treatment, both a) On a regular schedule (not just as needed or rescue doses) for the control of pain or dyspnea for at least 2 weeks before the first dose of methylnaltrexone, and b) On a stable opioid regimen for at least 3 days before the first dose of methylnaltrexone. This is defined as no dose reduction of \>/\= 50%, dose increases are permitted. 7\. If a subject uses a combination of short\- and long\-acting (including continuous administration) opioids, the short\-acting opioid should preferably be of the same type as the long\-acting opioid. If the subject uses a different type of short\-acting opioid than the long\-acting opioid, the subject is allowed to enter the study if he/she has used this short\-acting opioid /\= 3 days before the first dose of methylnaltrexone. This is defined as at least one type of laxative in an adequate dosing regimen, (e.g. macrogol 2 packets daily, magnesium(hydr)oxide 500 mg three times daily, bisacodyl 10 mg daily or sennoside A\+B 10 ml daily) or at least two types of laxatives in a suboptimal dose with patient characteristics hampering optimal treatment. 11\. If the subject is a woman with presumed child bearing potential; negative urine pregnancy test at screening 12\. Surgically sterile or agrees to use a medically acceptable method of birth control or practice sexual abstinence for the duration of the methylnaltrexone treatment and the following 15 days. \~ \* including laxation after rescue laxative or enema \~ not necessary for postmenopausal women
排除标准
- •1\. Previous treatment with methylnaltrexone 2\. Known or suspected mechanical gastrointestinal obstruction 3\. Presence of an other cause of bowel dysfunction that is considered to be a major contribution to the constipation according to investigator 4\. Presence of a peritoneal catheter for intraperitoneal chemotherapy or dialysis 5\. Clinically relevant active diverticular disease 6\. History of bowel surgery within 10 days before first dose of methylnaltrexone 7\. Fecal ostomy 8\. Use of vinca alkaloids within previous 4 months 9\. Body weight \<38 kg 10\. Renal failure defined as EGFR \<30 ml/min per 1\.73m2 or requires dialysis. 11\. Known or suspected allergy to methylnaltrexone or similar compounds (e.g. naltrexone or naloxone) 12\. Participation in a study with investigational products within 30 days before first dose of methylnaltrexone. 13\. Pregnant or nursing 14\. Clinically important abnormalities that may interfere with participation or compliance to the study, determined by investigator Additional exclusion criteria for the immunologic and angiogenic analysis part of the study: 15\. Chemotherapy or treatment with tyrosine kinase inhibitor during 4 weeks before inclusion or treatment scheduled during participation in this study. 16\. Treatment with high dose corticosteroids during 2 weeks before inclusion in this study. This is defined as the equivalent of 30 mg of prednisone per day for \>/\= 2 consecutive days.
结局指标
主要结局
未指定
相似试验
已完成
4 期
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexoneconstipation10017977NL-OMON39494Vrije Universiteit Medisch Centrum195
进行中（未招募）
不适用
Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexoneEUCTR2012-000850-75-NLVU University Medical Center
已完成
2 期
An assessment about impression of oral Methylnaltrexone on time of beginning of the bowel sounds after abdominal hysterectomyPostprocedural disorders of genitourinary system, not elsewhere classified.Postprocedural disorder of genitourinary system, unspecifiedIRCT201104121946N8Vice Chancellor for research-Guilan University of Medical Sciences66
招募中
3 期
Comparison of the effect of methylprednisolone and dexamethasone in prime solutioIRCT20170620034666N2Isfahan University of Medical Sciences62
已完成
2 期
Methylphenidate in Myotonic Dystrophy Type 1Dystrophia Myotonica 1NCT01421992Laval University28